Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among ocular hypertension patients using electronic records
Author Affiliations & Notes
  • David Michael Wright
    Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
  • Augusto Azuara-Blanco
    Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
  • Chris Cardwell
    Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
  • Giovanni Montesano
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
  • David P. Crabb
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
  • Gus Gazzard
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Anthony J King
    Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
  • Rodolfo Hernández
    Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom
  • James E Morgan
    School of Optometry and Visual Sciences, Cardiff University, Cardiff, Cardiff, United Kingdom
  • Bethany Elora Higgins
    Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
  • Yemisi Takwoingi
    Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships   David Wright None; Augusto Azuara-Blanco None; Chris Cardwell None; Giovanni Montesano None; David Crabb Apellis, Code C (Consultant/Contractor), Apellis, Santen, Code F (Financial Support), Allergan/Abbvie, Janssen, Santen,Thea, Code R (Recipient); Gus Gazzard Alcon, Allergan, Belkin, Elios, Equinox, Genentech/Roche, Glaukos, Ivantis, McKinsey, Rayner, Reichert, Ripple Therapeutics, Santen, Sight Sciences, Thea, Vialase, Visufarma, Zeiss;, Code C (Consultant/Contractor), Thea, Santen; Honoraria: Alcon, Allergan, Belkin, Glaukos, Ivantis, Lumibird, McKinsey, Reichert, Sight Sciences, Thea;, Code F (Financial Support), Ivantis, Thea, Code R (Recipient), : Glaucoma UK, UK & Ireland Glaucoma Society, Code S (non-remunerative); Anthony King Thea, Abbvie, Code C (Consultant/Contractor); Rodolfo Hernández None; James E Morgan None; Bethany Higgins None; Yemisi Takwoingi None
  • Footnotes
    Support  National Institute of Health Research (UK) - Health Technology Assessment - Glaucoma Risk Prediction in ocular hypertension (GRIP)(NIHR131808).
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4051. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Michael Wright, Augusto Azuara-Blanco, Chris Cardwell, Giovanni Montesano, David P. Crabb, Gus Gazzard, Anthony J King, Rodolfo Hernández, James E Morgan, Bethany Elora Higgins, Yemisi Takwoingi; Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among ocular hypertension patients using electronic records. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4051.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To validate and update the OHTS-EGPS model predicting risk of conversion from ocular hypertension (OHT) to glaucoma using electronic medical records (EMR).

Methods : EMR data were extracted for patients newly diagnosed with OHT attending hospital glaucoma services in England. Inclusion criteria were: intra-ocular pressure (IOP) 22-32 mmHg in either eye, normal baseline visual field (VF) test, defined as Glaucoma Hemifield Test (GHT) ‘within normal range’ in a reliable VF test, at least two VF tests in total and no significant ocular co-morbidities.

Risk factors considered: age, ethnicity, sex, IOP, vertical cup-to-disc ratio, central corneal thickness, VF pattern standard deviation, family history of glaucoma, systemic hypertension, diabetes mellitus, and glaucoma treatment. Conversion to glaucoma was defined as two consecutive and reliable VF tests with GHT ‘outside normal limits’ and/or need for glaucoma surgery.

For validation, the OHTS-EGPS model was applied to predict a patient’s risk of developing glaucoma in 5 years. In the updating stage, the OHTS-model was re-fitted by re-estimating the baseline hazard and regression coefficients. The updated model was cross-validated and several variants of the updated model were explored. Measures of discriminative ability (c-index) and calibration (calibration slope) were calculated and pooled across hospitals using random effects meta-analysis.

Results : From a total of 138,461 patients from ten hospital glaucoma services in England, 9030 patients with OHT fitted the inclusion criteria. A total of 1530 (16.9%) patients converted to glaucoma during this follow-up period. The OHTS-EGPS model provided a pooled c-index of 0.61 (95% confidence interval: 0.60, 0.63), ranging from 0.55 to 0.67 between hospitals. The pooled calibration slope was 0.45 (0.38, 0.51), ranging from 0.25 to 0.64 among hospitals. The overall re-fitted model performed better than the OHTS-EGPS model, with a pooled c-index of 0.67 (0.65, 0.69), ranging from 0.65 to 0.75 between hospitals.

Conclusions : We externally validated the OHTS-EGPS model in a large English population. Re-fitting the model in the same population achieved modest improvements in performance. Further research on how these predictions might usefully be incorporated into clinical practice is warranted.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×